Pfizer Inc. (NYSE: PFE) faced a challenging start to the trading week as HSBC lowered its rating on the pharmaceutical giant, shifting the market's focus from the downgrade itself to the company's dividend coverage. The stock was trading at $23.665 in morning trade on Monday, down approximately 2.7%, giving the company a market capitalization of roughly $135.6 billion.
HSBC downgraded Pfizer to Hold from Buy, while also reducing its price target to $28 from $32. This decision came despite the stock's implied upside of about 18.3% from the current price, which was comparable to that of Merck and AbbVie, both of which HSBC maintained at Buy. The downgrade appears to reflect concerns over catalyst quality rather than a simple valuation gap.
At the current share price, Pfizer's annualized dividend of $1.72 per share yields approximately 7.3%. However, this payout consumes between 57% and 61% of the company's 2026 adjusted diluted EPS guidance of $2.80 to $3.00. This high payout ratio has raised questions about the sustainability of the dividend, especially given the lack of near-term rerating catalysts.
The downgrade follows Pfizer's own late-June trial readout for sigvotatug vedotin, which failed to show a statistically significant improvement in overall survival versus docetaxel in the overall population of a Phase 3 study. HSBC lowered its probability of success for the drug to 40% after this setback and increased its beta assumption for Pfizer to 0.85 from 0.78, citing fewer catalysts for a near-term rerating.
Despite the setback in lung cancer, Pfizer has a potential offset in breast cancer. The FDA recently approved Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for maintenance treatment of HR-positive, HER2-positive locally advanced or metastatic breast cancer. The PATINA trial showed a 24% reduction in the risk of progression or death with Ibrance added to anti-HER2 and endocrine therapy.
Technically, Pfizer's stock is under pressure, trading below its 20-day, 50-day, and 200-day exponential moving averages. To regain the 20-day EMA, the stock would need to rise about 4.7% to $24.77, while reaching the 200-day EMA would require an 8.5% gain to $25.68. The HSBC target of $28 implies an 18.3% upside from current levels.
In the first quarter, Pfizer's revenue rose 5% to $14.45 billion, but adjusted diluted EPS fell 18% to 75 cents. CFO David Denton reaffirmed the company's full-year 2026 financial guidance, which assumes no share repurchases for the year. The board has declared a third-quarter dividend of 43 cents per share, payable September 1 to holders of record as of July 24.
Investors will be closely watching Pfizer's ability to balance its dividend commitments with the need to invest in its pipeline, particularly in oncology, as the company navigates a period of limited near-term catalysts and a challenging technical setup.
